Market Overview

The global artificial intelligence in life sciences market size was valued at USD 2.9 Billion in 2024 and is projected to reach USD 16.7 Billion by 2033, growing at a CAGR of 21.5% during the forecast period 2025-2033. Growth is propelled by rising prevalence of complex diseases, increasing AI adoption in medical imaging, genomics research integration, and convergence with emerging technologies. The market report offers comprehensive insights on offerings, deployment, applications, and regional dynamics for the period 2025-2033.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Artificial Intelligence in Life Sciences Market Key Takeaways

• Current Market Size: USD 2.9 Billion in 2024
• CAGR: 21.5% (2025-2033)
• Forecast Period: 2025-2033
• The market growth is driven mainly by the surge in biomedical data from genomic sequences and electronic health records, necessitating powerful AI tools for management and analysis.
• AI accelerates drug discovery and development processes, substantially reducing time and costs.
• Increasing regulatory support and advancements in machine learning further propel market growth.
• Key trends include integration with cloud computing and IoT, AI-driven predictive disease models, and collaborative efforts between AI firms and pharmaceutical companies.
• North America holds the largest market share due to its advanced tech infrastructure, investments, and regulatory support.

Sample Request Link: https://www.imarcgroup.com/artificial-intelligence-in-life-sciences-market/requestsample

Market Growth Factors

Biomedical data surge and AI integration: The artificial intelligence in life sciences market is primarily driven by the escalating volume of biomedical data stemming from genomic sequences and electronic health records. This vast data influx necessitates the deployment of robust AI tools, enabling effective management and comprehensive analysis. Such AI integration is crucial for handling complex biological datasets, ensuring precision and efficiency in research activities.

Acceleration of drug discovery and development: AI technologies markedly expedite drug discovery and development, traditionally a lengthy, costly process. Machine learning algorithms analyze extensive datasets—biological, chemical, clinical trial data, and existing drug databases—to rapidly identify promising drug candidates. This acceleration reduces time and costs substantially, increasing the efficiency of the pharmaceutical development pipeline.

Regulatory and technological advancements: Regulatory bodies increasingly support AI integration within clinical settings, facilitating market growth. Meanwhile, advancements in machine learning and computational algorithms enhance AI capabilities, enabling sophisticated applications such as predictive disease modeling and personalized medicine. These factors collectively contribute to the growing adoption of AI in life sciences, strengthening the ecosystem for innovation.

Market Segmentation

By Offering:

• Software: Includes AI tools, platforms, and applications designed to analyze vast life sciences data using machine learning, natural language processing, and deep learning. Software dominates due to its scalability, adaptability, and ability to support diverse research needs like drug target identification and patient stratification.
• Hardware: Not explicitly described in source.
• Services: Not explicitly described in source.

By Deployment:

• On-premises: Not explicitly described in source.
• Cloud-based: Dominates the market by providing scalability, cost-effectiveness, and collaboration advantages for complex AI applications. Cloud deployment supports dynamic resource allocation, pay-as-you-go pricing, and remote accessibility for researchers.

By Application:

• Drug Discovery: The largest segment; AI accelerates drug candidate identification, predicts pharmacokinetics and toxicity, and supports drug repurposing strategies to find new therapeutic uses for existing drugs.
• Medical Diagnosis: Not explicitly described in source.
• Biotechnology: Not explicitly described in source.
• Clinical Trials: Not explicitly described in source.
• Precision and Personalized Medicine: AI analyzes genetic profiles and health data to tailor treatments, improving efficacy and minimizing side effects.
• Patient Monitoring: Not explicitly described in source.

Regional Insights

North America dominates the artificial intelligence in life sciences market, driven by advanced technological infrastructure, substantial investments in AI and healthcare, and strong regulatory support. The region benefits from high private and government funding, robust intellectual property frameworks, and extensive healthcare infrastructure including large patient populations and comprehensive electronic health records. This combination creates an optimal environment for AI innovation and application in life sciences.

Recent Developments & News

In 2024, Atomwise's AIMS initiative demonstrated success in drug discovery, with its AtomNet AI Platform identifying novel chemical matter for 235 of 318 targets, as published in Nature Scientific Reports. Additionally, IBM partnered with the Canadian government and Quebec to invest approximately CAD 187 million to advance semiconductor industry capabilities at IBM Canada's Bromont plant, aiming to boost R&D, create jobs, and strengthen supply chains.

Key Players

• AiCure LLC
• Apixio Inc. (Centene Corporation)
• Atomwise Inc
• Enlitic Inc.
• International Business Machines Corporation
• Insilico Medicine Inc.
• Nuance Communications Inc.
• NuMedii Inc.
• Sensely Inc.
• Sophia Genetics SA

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

?Get Custom Market Research for Your Business?

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302